Aptose Biosciences Inc. Contracts & Agreements
34 Contracts & Agreements
- Business Finance (25 contracts)
- Human Resources (5)
- Intellectual Property (1)
- Uncategorized (3)
- Funding Satisfaction Agreement (Filed With SEC on January 30, 2024)
- Underwriting Agreement (Filed With SEC on January 30, 2024)
- Form of Hanmi Warrant (Filed With SEC on January 30, 2024)
- Form of Placement Agent Warrant (Filed With SEC on January 30, 2024)
- Form of Public Offering Warrant (Filed With SEC on January 30, 2024)
- Form of Underwriter Warrant (Filed With SEC on January 30, 2024)
- Subscription Agreement (Filed With SEC on January 30, 2024)
- Amended and Restated Investors Rights Agreement (Filed With SEC on January 30, 2024)
- Form of Underwriters Warrant (Filed With SEC on December 29, 2023)
- Form of Underwriting Agreement (Filed With SEC on December 29, 2023)
- Form of Pre-Funded Warrant Offered in this Offering (Filed With SEC on December 11, 2023)
- Form of Warrant Offered in this Offering (Filed With SEC on December 11, 2023)
- Form of Underwriting Agreement (Filed With SEC on December 11, 2023)
- Investor Rights Agreement (Filed With SEC on September 12, 2023)
- Subscription Agreement (Filed With SEC on September 12, 2023)
- Common Share Purchase Agreement, dated as of May 25, 2023, by and between the Company and Keystone Capital Partners, LLC (Filed With SEC on May 26, 2023)
- Registration Rights Agreement, dated as of May 25, 2023, by and between the Company and Keystone Capital Partners, LLC (Filed With SEC on May 26, 2023)
- Equity Distribution Agreement, dated December 9, 2022, among Aptose Biosciences Inc. and JonesTrading Institutional Services LLC (Filed With SEC on December 12, 2022)
- Employment Agreement, dated June 27, 2022, between Aptose Biosciences Inc. and Fletcher Payne (Filed With SEC on June 28, 2022)
- Employment Agreement dated June 3, 2019 between Aptose Biosciences Inc. and Philippe Ledru (Filed With SEC on April 11, 2022)
- Description of Securities (Filed With SEC on March 22, 2022)
- Exclusive License Agreement, dated November 4, 2021, by and between Hanmi Pharmaceutical Co. Ltd. and Aptose Biosciences Inc (Filed With SEC on November 4, 2021)
- Consulting Agreement dated March 26, 2021 between Aptose Biosciences Inc. and Gregory K. Chow (Filed With SEC on May 4, 2021)
- Description of Securities (Filed With SEC on March 23, 2021)
- Underwriting Agreement, dated July 15, 2020, between Aptose Biosciences Inc. and Piper Sandler & Co (Filed With SEC on July 16, 2020)
- Equity Distribution Agreement, dated May 5, 2020, among Aptose Biosciences Inc., Piper Sandler & Co. and Canaccord Genuity LLC (Filed With SEC on May 5, 2020)
- Form of Executive Employment Agreement, dated December 4, 2019, between the Company and Dr. Rafael Bejar (Filed With SEC on March 10, 2020)
- Description of Securities (Filed With SEC on March 10, 2020)
- Underwriting Agreement, dated December 16, 2019 between Aptose Biosciences Inc. and Piper Jaffray & Co (Filed With SEC on December 17, 2019)
- Form of Executive Employment Agreement, dated June 3, 2019, between the Company and Dr. Jotin Marango (Filed With SEC on August 6, 2019)
- Underwriting Agreement, dated May 30, 2019 among Aptose Biosciences Inc., RBC Capital Markets, LLC and Canaccord Genuity LLC (Filed With SEC on May 30, 2019)
- Equity Distribution Agreement, dated May 24, 2019, among Aptose Biosciences Inc., Piper Jaffray & Co. and Canaccord Genuity LLC (Filed With SEC on May 24, 2019)
- Form of Common Share Purchase Agreement dated May 7, 2019 by and between the Company and Aspire Capital Fund, LLC (Filed With SEC on May 7, 2019)
- Form of Registration Rights Agreement dated May 7, 2019 by and between the Company and Aspire Capital Fund, LLC (Filed With SEC on May 7, 2019)